Global Tumor NGS Genetic Testing Supply, Demand and Key Producers, 2023-2029

Global Tumor NGS Genetic Testing Supply, Demand and Key Producers, 2023-2029

The global Tumor NGS Genetic Testing market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Tumor NGS Genetic Testing is to use high-throughput sequencing to understand tumors at the genetic level, detect and quantify the genetic components that drive tumors.

This report studies the global Tumor NGS Genetic Testing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Tumor NGS Genetic Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor NGS Genetic Testing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Tumor NGS Genetic Testing total market, 2018-2029, (USD Million)

Global Tumor NGS Genetic Testing total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Tumor NGS Genetic Testing total market, key domestic companies and share, (USD Million)

Global Tumor NGS Genetic Testing revenue by player and market share 2018-2023, (USD Million)

Global Tumor NGS Genetic Testing total market by Type, CAGR, 2018-2029, (USD Million)

Global Tumor NGS Genetic Testing total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Tumor NGS Genetic Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., Burning Rock Biotech., NovogeneCo.,Ltd., Nanjing Shihejiyin Technology, Inc. and Amoy Diagnostics Co.,Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumor NGS Genetic Testing market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Tumor NGS Genetic Testing Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Tumor NGS Genetic Testing Market, Segmentation by Type
Liquid Biopsy (Blood Sample)
Tissue Biopsy

Global Tumor NGS Genetic Testing Market, Segmentation by Application
Companion Diagnostics
Early Cancer Screening
Drug Discovery

Companies Profiled:
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
Geneis（Beijing）Co.Ltd.
HaploX

Key Questions Answered

1. How big is the global Tumor NGS Genetic Testing market?

2. What is the demand of the global Tumor NGS Genetic Testing market?

3. What is the year over year growth of the global Tumor NGS Genetic Testing market?

4. What is the total value of the global Tumor NGS Genetic Testing market?

5. Who are the major players in the global Tumor NGS Genetic Testing market?

6. What are the growth factors driving the market demand?